PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Eirgen Pharma Ltd.

USPTO PatentsView assignee record - 13 granted patents across 4 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Eirgen ranks #21,055 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 4 technology areas.

#21,055
of 49,997 US assignees by volume
Top 32%
by Innovation Score (41.8/100)
20.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R21055 · Foreign Corporation #21,055 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 13 grants
  • MID-PACK #21,055/49,997
  • PHOTO-FINISH Edge Surgical
  • CPC-NARROW A61P · 4 areas
  • INNOV-PAR 41.8/100
  • CLAIMS-DENSE 20.4 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Edge Surgical, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Eirgen’s 41.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Eirgen

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Eirgen's Innovation Score is 41.8/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Eirgen?

Each dot is one of Eirgen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Eirgen’s own 20.4 claims/patent is ABOVE the 18.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Eirgen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 12.912.91313.1 0102030 Granted patents (volume) Avg claims / patent Edge Surgical, Inc. - 13, 18.62Edge SurgicalEdifire LLC - 13, 24.08EdifireEdra S.P.A. - 13, 3.38Edra S P AEgalet Ltd. - 13, 27.31EgaletEkato Rühr-und Mischtechnik GmbH - 13, 16.69Ekato Rühr-und Mi…Elcam Medical Agricultural Cooperative Association Ltd - 13, 20.85Elcam Medical Agr…Eleappower Ltd. - 13, 21.38EleappowerElectric Power Research Institute, China Southern Power Grid - 13, 10.69Electric Power Re…Eirgen Pharma Ltd. - 13, 20.38Eirgen Pharma
Eirgen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Eirgen's grants concentrate

Eirgen Pharma Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (4 grants) versus a trough of 2 in 2022. By volume, Eirgen sits between Edge Surgical, Inc. and Electric Power Research Institute, China Southern Power Grid.

Eirgen's three-year grant acceleration

Eirgen Pharma Ltd. shows 8 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Eirgen's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Eirgen holds 13 patents at rank #21,049, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Eirgen

By rank, the assignees closest to #21,049 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Eirgen's primary technology class.

Eirgen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 20212022202320242025 1
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Eirgen Pharma Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 4 30.8%
2022 2 15.4%
2023 4 30.8%
2024 2 15.4%
2025partial year 1 7.7%

Which technologies does Eirgen Pharma Ltd. patent most?

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Eirgen Pharma Ltd.'s patent record in context - here's where to go next.

  • Eirgen Pharma Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #21,055 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Eirgen Pharma Ltd. against Edge Surgical, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 41.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.